<DOC>
	<DOCNO>NCT00927251</DOCNO>
	<brief_summary>This study design show new lead , pace leave bottom chamber ( left ventricle ) heart , safe . Using lead left side heart show potentially improve heart failure symptom . The shape size new lead may make good choice patient physician .</brief_summary>
	<brief_title>Model 4296 Left Ventricular ( LV ) Lead Study</brief_title>
	<detailed_description>This study prospective , multi-center , non-randomized design trial . All consent patient meet inclusion exclusion criterion may receive investigational lead . The study design statistical power show safety one-month implant .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Cardiac Resynchronization Therapy ( CRT ) /Cardiac Resynchronization TherapyDefibrillator ( CRTD ) indication accord European Society Cardiology/American College Cardiology/American Heart Association ( ESC/ACC/AHA ) guideline On optimal medical treatment accord investigator opinion Indicated implantable cardioverter defibrillator ( ICD ) CRTD implant Patient consent Geographically stable Left Ventricular ( LV ) lead implant attempt last 30 day Unstable angina acute myocardial infarction ( MI ) past 30 day Coronary artery bypass graft ( CABG ) percutaneous transluminal coronary angioplasty ( PTCA ) past 90 day Contraindicated transvenous pace Heart transplant Contraindicated le 1 milligram ( mg ) dexamethasone acetate Enrolled intend participate concurrent drug and/or device study would confound result Life expectancy short duration study Exclusion criterion require local law Unable tolerate urgent thoracotomy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>heart failure</keyword>
	<keyword>cardiac pacing</keyword>
	<keyword>cardiac resynchronization therapy</keyword>
	<keyword>leave ventricular lead</keyword>
</DOC>